A K Alame-Emane1, P Xu2, C Pierre-Audigier3, V Cadet-Daniel4, X Shen5, M Sraouia6, J F Djoba Siawaya7, H Takiff8, Q Gao2, B Gicquel9. 1. Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France; Research and Specialised Diagnostics Unit, National Laboratory of Public Health, Libreville, Gabon. 2. Key Laboratory of Medical Molecular Virology, Institutes of Biomedical Sciences and Institute of Medical Microbiology, Shanghai Medical College, Fudan University, Shanghai, China. 3. Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France; Laboratoire de Bactériologie, Bichat-Claude Bernard Hospital, Paris, France. 4. Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France. 5. Department of Tuberculosis Control, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China. 6. Laboratoire de Bactériologie, Bichat-Claude Bernard Hospital, Paris, France. 7. Research and Specialised Diagnostics Unit, National Laboratory of Public Health, Libreville, Gabon. 8. Laboratorio de Genética Molecular, Centro de Microbiologıa y Biologıa Celular, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela. 9. Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France; Emerging Bacterial Pathogens Laboratory, Institut Pasteur of Shanghai, Shanghai, China.
Abstract
BACKGROUND: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (TB) constitute a major public health concern. OBJECTIVE: To determine the timing of pncA mutations that confer pyrazinamide (PZA) resistance in relation to mutations conferring resistance to isoniazid (INH) and rifampicin (RMP). DESIGN: Isolates from two major urban centres--Paris (101 strains) and Shanghai (171 strains)--were investigated for the association of pncA mutations with resistance to drugs other than PZA. RESULTS: The proportion of pncA mutations found in INH-monoresistant strains was not increased. CONCLUSION: pncA mutations associated with PZA resistance were found almost exclusively in MDR-TB strains, underlining the importance of determining PZA resistance when treating MDR- or XDR-TB.
BACKGROUND: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (TB) constitute a major public health concern. OBJECTIVE: To determine the timing of pncA mutations that confer pyrazinamide (PZA) resistance in relation to mutations conferring resistance to isoniazid (INH) and rifampicin (RMP). DESIGN: Isolates from two major urban centres--Paris (101 strains) and Shanghai (171 strains)--were investigated for the association of pncA mutations with resistance to drugs other than PZA. RESULTS: The proportion of pncA mutations found in INH-monoresistant strains was not increased. CONCLUSION: pncA mutations associated with PZA resistance were found almost exclusively in MDR-TB strains, underlining the importance of determining PZA resistance when treating MDR- or XDR-TB.
Authors: Emily A Kendall; Shelly Malhotra; Sarah Cook-Scalise; David W Dowdy; Claudia M Denkinger Journal: Clin Infect Dis Date: 2020-12-31 Impact factor: 9.079